Psychopharmacologia

Editorial Board

D. Bovet, Sassari · J. O. Cole, Boston · J. Delay, Paris · J. Elkes, Baltimore
M. Hamilton, Leeds · H. Isbell, Lexington · E. Jacobsen, København
M. E. Jarvik, Los Angeles · S. S. Kety, Boston · C. Kornetsky, Boston · E. Rothlin, Basel
M. Shepherd, London · Hannah Steinberg, London · E. Strömgren, Risskov
A. Wikler, Lexington

Managing Editors

J. O. Cole · M. Hamilton · E. Jacobsen · C. Kornetsky

Advisory Board

Neurophysiologia

F. Bremer, Bruxelles
J. C. Eccles, Amherst
A. Fessard, Paris
G. W. Harris, London
G. Moruzzi, Pisa
J. Z. Young, London

Neuropharmacologia

M. Adler, Philadelphia
P. B. Bradley, Birmingham
A. Carlsson, Göteborg
H. Coper, Berlin
E. Domino, Ann Arbor
D. Efron, Chevy Chase
U. S. von Euler, Stockholm
W. S. Feldberg, London
S. Garattini, Milano
J. Harvey, Iowa City
L. E. Hollister, Palo Alto
O. Hornykiewicz, Toronto
E. Hosoya, Tokyo
S. Irwin, Portland
K. F. Killam, Palo Alto
I. P. Lapin, Leningrad
L. Lasagna, Baltimore
E. Marley, London
W. R. Martin, Lexington
H. O. Schild, London
S. Sjöqvist, Stockholm
F. Sulser, Nashville
R. Taber, Bloomfield
A. Weissmann, Groton, Conn.
T. Yanagita, Kawasaki
E. Zaimis, London

Neurochimia

S. Barondes, La Jolla
H. Blaschko, Oxford
J. Glowinski, Paris
D. Richter, Epsom
R. Rodnight, London
S. Udenfriend, Bethesda
H. Weil-Malherbe, Washington

Neurologia

H. Gastaut, Marseille
P. van Gehuchten, Bruxelles

Psychiatria

J. Angst, Zürich
H. Brill, New York
P. Deniker, Paris
P. Dick, Genève
M. Fink, New York
F. Flügel, Erlangen
S. Gershon, New York
H. Hippius, München
J. Jaffe, Chicago
R. T. Jones, San Francisco
G. Klerman, Boston
N. S. Kline, Orangeburg
M. H. Lader, London
A. J. Lewis, London
O. Lingjærde, Oslo
P. Pichot, Paris
K. Rickels, Philadelphia
J. M. Rose, Leeds
J. Schildkraut, Boston
C. Shagass, Philadelphia
J. R. Smythies, Edinburgh
O. Vinar, Praha

Psychologia

J. Appel, Chicago
H. Barry III, Pittsburgh
P. Carlton, New Brunswick
C. K. Connors, Boston
P. B. Dews, Boston
A. DiMascio, Boston
H. J. Eysenck, London
S. Fisher, Boston
S. C. Goldberg, Chevy Chase
S. Grossman, Chicago
H. Hanson, West Point
H. E. Hill, Lexington
C. R. B. Joyce, Basel
M. Katz, Chevy Chase
R. Kelleher, Boston
V. Laties, Rochester
A. Latz, Tel-Aviv
R. Lipman, Rockville
A. Lubin, San Diego
A. E. Maxwell, London
J. L. McGaugh, Irvine
N. Mello, Washington
A. Mirsky, Boston
S. Norton, Kansas City
D. Overton, Philadelphia
C. Schuster, Chicago
A. Summerfield, London
T. Thompson, Minneapolis
O. Zangwill, Cambridge

Volume 26 · 1972

SPRINGER-VERLAG · BERLIN · HEIDELBERG · NEW YORK

The exclusive copyright for all languages and countries, including the right for photomechanical and any other reproductions, also in microform, is transferred to the publisher.

The use in this journal of registered or trade names, trademarks etc. without special acknowledgement does not imply that such names, as defined by the relevant protections laws, may be regarded as unprotected and thus free for general use.

Springer-Verlag Berlin Heidelberg New York

Printed in Germany by Wiesbadener Graphische Betriebe GmbH, Wiesbaden

© by Springer-Verlag Berlin Heidelberg 1972

Contents

Subject Index VI

Abe, K., Kiriike, N., Suzuki, T.: Sulpiride in Stupor 91
Albus, K., see Herz, A., et al. 219
Angrist, B., Shopsin, B., Gershon, S., Wilk, S.: Metabolites of Monoamines in Urine and Cerebrospinal Fluid, after Large Dose Amphetamine Administration 1
Angrist, B., see Rotrosen, J., et al. 185
Ayala, F., see Fernández-Guardiola, A., et al. 285

Bauer, V., Kadlecová, O.: Studies on the Central Nervous System Actions of Papaverine. II. On the Possible Mechanisms of Early and Long-Lasting Sleep Changes 275
Bauer, V., Sur, R. N.: Studies on the Central Nervous System Actions of Papaverine. I. The Action on Sleep Cycle in the Rat 263
Berger, B. B., see Voss, E. W., Jr. 140
Bernasconi, S., see Valzelli, L. 255
Boissier, J. R., see Soubrié, P., et al. 317
Borg, G., Edström, C.-G., Linderholm, H., Marklund, G.: Changes in Physical Performance Induced by Amphetamine and Amobarbital 10
Boulu, R., Rapin, J. R., Lebas, M., Jacquot, C.: Action centrale de l'amphétamine, de l'éphédrine et de leur dérive p-hydroxylé, après lésion unilatérale du faisceau nigrostriatal chez le rat 54

Cannizzaro, G., Nigito, S., Provenzano, P. M., Vitikova, T.: Modification of Depressant and Disinhibitory Action of Flurazepam during Short Term Treatment in the Rat 173
Carlsson, A., Engel, J., Svensson, T. H.: Inhibition of Ethanol-Induced Excitation in Mice and Rats by α-Methyl-p-tyrosine 307
Chippendale, T. J., Zawolkow, G. A., Russell, R. W., Overstreet, D. H.: Tolerance to Low Acetylcholinesterase Levels: Modification of Behavior without Acute Behavioral Change 127
Conners, C. K., Taylor, E., Meo, G., Kurtz, M. A., Fournier, M.: Magnesium Pemoline and Dextroamphetamine: A Controlled Study in Children with Minimal Brain Dysfunction 321
Contreras, C., see Fernández-Guardiola, A., et al. 285
Cooper, A. J., Ismail, A. A. A.: A Pilot Study of Mesterolone in Impotence . . 379
Corrêa, D. L., see Todorov, J. C., et al. 395

Delini-Stula, A.: Increased Sensitivity to Neuroleptics in Rats with Lesions of the Central Nervous System 84
Dunkley, B., Sanghvi, I., Friedman, E., Gershon, S.: Comparison of Behavioral and Cardiovascular Effects of L-DOPA and 5-HTP in Conscious Dogs . . . 161

Edström, C.-G., see Borg, G., et al. 10
Elo, H., Tirri, R.: Effect of Forced Motility on the Noradrenaline and 5-Hydroxytryptamine Metabolism in Different Parts of the Rat Brain 195
Elsmore, T. F.: Effects of Delta-9-Tetrahydrocannabinol on Temporal and Auditory Discrimination Performances of Monkeys 62
Engel, J., see Carlsson, A., et al. 307

Fernández-Guardiola, A., Lerdo de Tejada, A., Contreras, C., Salgado, A., Ayala, F.: Polygraphic Study in Man to Differentiate Sleep-Inducing Action of Hypnotics 285

Findley, J. D., Robinson, W. W., Pelegrino, L.: Addiction to Secobarbital and Chlordiazepoxide in the Rhesus Monkey by Means of a Self-Infusion Preference Procedure 93
Fournier, M., see Conners, C. K., et al. 321
Freeman, B. J., see Herman, S. J., et al. 146
Fried, P. A., see Potvin, R. J. 369
Friedman, E., see Dunkley, B., et al. 161

Gallager, D. W., Sanders-Bush, E., Sulser, F.: Dissociation between Behavioral Effects and Changes in Metabolism of Cerebral Serotonin Following Δ^9-Tetrahydrocannabinol 337
Gauron, E. F., Rowley, V. N.: Critical Periods for Drug Administration Effects in Infancy 73
Gershon, S., see Angrist, B., et al. 1
Gershon, S., see Dunkley, B., et al. 161
Gershon, S., see Rotrosen, J., et al. 185
Glazer, H. I.: Physostigmine and Resistance to Extinction 387
Goldstein, L., see Nelsen, J. M., et al. 347
Gorayeb, S. R. P., see Todorov, J. C., et al. 395
Graeff, F. D., see Todorov, J. C., et al. 395
Griffiths, W. J., see Rundell, O. H., et al. 201
Guschwan, A., see Meltzer, H. Y., et al. 44

Harris, R. T., Waters, W., McLendon, D.: Behavioral Effects in Rhesus Monkeys of Repeated Intravenous Doses of Δ-9-Tetrahydrocannabinol 297
Hassan, S. Z., see Meltzer, H. Y., et al. 44
Herman, S. J., Freeman, B. J., Ray, O. S.: The Effects of Multiple Injections of Morphine Sulfate on Shuttle-Box Behavior in the Rat 146
Herring, B.: The Effect of 1-Δ^1-trans-Tetrahydrocannabinol on Learning and Retention of Avoidance Performance in Rats 401
Herz, A., Teschemacher, Hj., Albus, K., Zieglgänsberger, S.: Morphine Abstinence Syndrome in Rabbits Precipitated by Injection of Morphine Antagonists into the Ventricular System and Restricted Parts of It 219
Holzmann, P. S., see Meltzer, H. Y., et al. 44

Ismail, A. A. A., see Cooper, A. J. 379

Jacquot, C., see Boulo, R., et al. 54

Kadlecová, O., see Bauer, V. 275
Kiriike, N., see Abe, K., et al. 91
Kral, P. A., Omer, V. V. St.: Beta-Adrenergic Receptor Involvement in the Mediation of Learned Taste Aversions 79
Kumar, R., see Stolerman, J. P. 19
Kurtz, M. A., see Conners, C. K., et al. 321

Lapin, I. P.: Interaction of Kynurenine and Its Metabolites with Tryptamine, Serotonin and Its Precursors and Oxotremorine 237
Lebas, M., see Boulu, R., et al. 54
Lerdo de Tejada, A., see Fernández-Guardiola, A., et al. 285
Lester, B. K., see Rundell, O. H., et al. 201
Linderholm, H., see Borg, G., et al. 10

Marklund, G., see Borg, G., et al. 10
McLendon, D., see Harris, R. T., et al. 297
Meltzer, H. Y., Holzman, P. S., Hassan, S. Z., Guschwan, A.: Effects of Phencyclidine and Stress on Plasma Creatine Phosphokinase (CPK) and Aldolase Activities in Man 44
Meo, G., see Conners, C. K., et al. 321

Naik, S. R., see Sethy, V. H., et al. 249
Nelsen, J. M., Goldstein, L.: Improvement of Performance on an Attention Task with Chronic Nicotine Treatment in Rats 347

Nigito, S., see Cannizzaro, G., et al. 173
Nybäck, H., Sedvall, G.: Effect of Chlorpromazine and Some of Its Metabolites on Synthesis and Turnover of Catecholamines Formed from ^{14}C-Tyrosine in Mouse Brain 155
Nymark, M.: Apomorphine Provoked Stereotypy in the Dog 361

Omer, V. V. St., see Kral, P. A. 79
Overstreet, D. H., see Chippendale, T. J., et al. 127

Pelegrino, L., see Findley, J. D., et al. 93
Potvin, R. J., Fried, P. A.: Acute and Chronic Effects on Rats of (−)Δ^1-trans-Tetrahydrocannabinol on Unlearned Motor Tasks 369
Provenzano, P. M., see Cannizzaro, G., et al. 173

Rapin, J. R., see Boulu, R., et al. 54
Ray, O. S., see Herman, S. J., et al. 146
Robinson, W. W., see Findley, J. D., et al. 93
Rosecrans, J. A., see Schechter, M. D. 313
Rotrosen, J., Wallach, M. B., Angrist, B., Gershon, S.: Antagonism of Apomorphine Induced Stereotypy and Emesis in Dogs by Thioridazine, Haloperidol, and Pimozide 185
Rowley, V. N., see Gauron, E. F. 73
Rundell, O. H., Lester, B. K., Griffiths, W. J., Williams, H. L.: Alcohol and Sleep in Young Adults 201
Russell, R. W., see Chippendale, T. J., et al. 127

Salgado, A., see Fernández-Guardiola, A., et al. 285
Sanders-Bush, E., see Gallager, D. W., et al. 337
Sanghvi, I., see Dunkley, B., et al. 161
Schechter, M. D., Rosecrans, J. A.: Lysergic Acid Diethylamide (LSD) as a Discriminative Cue: Drugs with Similar Stimulus Properties 313
Schoonhoed, L., see Soubrié, P., et al. 317
Schuster, C. R., see Wilson, M. C. 115
Sedvall, G., see Nybäck, H. 155
Sethy, V. H., Naik, S. R., Sheth, U. K.: Effect of Reserpine and Tetrabenazine on Tremorine Analgesia in Mice 249
Sheth, U. K., see Sethy, V. H., et al. 249
Shopsin, B., see Angrist, B., et al. 1
Simon, P., see Soubrié, P., et al. 317
Soubrié, P., Schoonhoed, L., Simon, P., Boissier, J. R.: Conflict Behavior in a Heated-Floor Maze: Effects of Oxazepam 317
Stolerman, I. P., Kumar, R.: Regulation of Drug and Water Intake in Rats Dependent on Morphine 19
Sulser, F., see Gallager, D. W., et al. 337
Sur, R. N., see Bauer, V. 263
Suzuki, T., see Abe, K., et al. 91
Svensson, T. H., see Carlsson, A., et al. 307

Taylor, E., see Conners, C. K., et al. 321
Teschemacher, Hj., see Herz, A., et al. 219
Tirri, R., see Elo, H. 195
Todorov, J. C., Gorayeb, S. R. P., Corrêa, D. L., Graeff, F. G.: Effects of Amphetamine on Choice Behavior of Pigeons 395

Valzelli, L., Bernasconi, S.: Effects of N-(Ethyl-2 Pyrrolidinyl-Methyl)-2-Methoxy-5-Sulfamoil-Benzamide (Sulpyrid) on the Central Nervous System in Rats and Mice 255
Vitikova, T., see Cannizzaro, G., et al. 173
Voss, E. W., Jr., Berger, B. B.: Neutralization of LSD by Active Immunization 140

Wallach, M. B., see Rotrosen, J., et al. 185
Waters, W., see Harris, R. T., et al. 297
Wilk, S., see Angrist, B., et al. 1

Williams, H. L., see Rundell, O. H., et al. 201
Wilson, M. C., Schuster, C. R.: The Effects of Chlorpromazine on Psychomotor Stimulant Self-Administration in the Rhesus Monkey 115
Wray, S. R.: A Correlative Evaluation of Cyclazocine, LSD and Naloxone on Continuous Discriminated Avoidance in Rats 29

Zawolkow, G. A., see Chippendale, T. J., et al. 127
Zieglgänsberger, S., see Herz, A., et al. 219

Indexed in Current Contents

Subject Index

A

Addiction, multiple 93
Aggressiveness by isolation 255
Alcohol 201
Aldolase 44
Alpha-methyl-p-tyrosine 127
Alpha rhythm 285
Amitriptyline 361
Amobarbital 10
Amphetamine 1, 10, 54, 395
d-Amphetamine 115
*p*OH Amphetamine 54
Analgesia 249, 337
Anthranilic acid 237
Anticholinergics 361
Antihistaminics 361
Apomorphine 185, 361
Arousal 347
Attention task 347
Audition 62
Avoidance 29, 146, 401

B

Behavior 161
Beta-adrenergic agonist 79
—, antagonist 79
Brain amines 255
—, dysfunction, minimal 321
—, noradrenaline 195

C

Catalepsy 84
Catecholamine synthesis inhibition 307
Cerebrospinal fluid 1
Chemoreceptor trigger zone 361
Chlordiazepoxide 93
—, promazine 115
—, metabolites 155
Choice 395
—, procedure 93
Cholinesterase activity 127
Cholinergic agents 84
Chronic drug effects 297
—, nicotine 347
CNS lesions 84
Cocaine 115
Concurrent schedules 395
Conditioned taste-aversions 79
Conflict behavior 317
Corpus striatum 361
Creatine phosphokinase 44
Critical periods 73
Cyclazocine 29

D

Δ^1-trans-tetrahydrocannabinol 369, 401
Δ^9-tetrahydrocannabinol 62, 297, 337
Depressant action 173
Developmental psychopharmacology 73
Dextroamphetamine 321
Diazepam 361
Diisopropyl fluorophosphate 127
Discrimination 62
Discriminative avoidance 29
Disinhibitory action 173
Dogs 161, 185, 361
Dopamine 54
—, synthesis 155
L-DOPA 161
DL-DOPA 249
Dose effects, papaverine 263
Drinkometers 19
Drug effects in infancy 73

E

Early experience effects 73
Electroencephalography 201
Emesis 185
Ephedrine 54
*p*OH Ephedrine 54

Ethanol 307
Exploratory activity 255
Extinction 387
Extrapyramidal effects 185

F

Flurazepam 173
Forced motility 195

H

Haloperidol 185
Hippocampus 387
Homovanillic acid 1
5-HTP 161
dl-5-HTP 249
Human subjects 1, 10, 44, 91, 201, 285, 321, 379
3-Hydroxyanthranilic acid 237
5-Hydroxy indoleacetic acid 1
3-Hydroxykynurenine 237
5-Hydroxytryptamine 195
Hypnotics 285

I

Immune neutralization 140
Impotence 379
Intravenous route 297
Intraventricular injection 219

K

Kynurenine 237

L

Learning 401
Long-term drug effects 73
LSD 29, 148, 313

M

Magnesium pemoline 321
Marihuana 62
Maze 317
Memory 401
Mescaline 313
Mesterolone 379
Metabolism of serotonin 337
3-Methoxy-4-hydroxy-phenyl glycol 1
Methylphenidate 115
Methyl scopolamine 127
Methysergide 161
Metochlopramide 361
MHPG 1
Mice 140, 155, 237, 249, 255, 307
Monkeys 62, 93, 115, 297
Monoamine metabolites 1
Morphine 146
—, abstinence syndrome 219
—, dependence 19
Motivation 10
Motor activity 195, 307
Motor skills 369
Muricide behavior 255

N

Nalorphine 219
Naloxone 29
Neuroleptics 84, 155, 185, 361
Nicotine 347
Nicotinic acid 237
Nigrostriatum 54

O

Oxazepam 317
Oxotremorine 237

P

Papaverine 263, 275
PCPA 161
Phenyclidine 44
Phenmetrazine 115
Phenothiazines 73, 155
Phenoxybenzamine 361
Physical performance 10
Physostigmine 387
Picolinic acid 237
Pigeons 395
Pimozide 185
Pipradol 115
Preference 93
Primates 93
Psilocybin 313
Psychogalvanic reflex 285

Q

Quinolinic acid 237

R

Rabbits 219
Rats 19, 29, 54, 73, 79, 84, 127, 146, 173, 195, 263, 275, 307, 313, 317, 337, 347, 369, 387, 401
Reaction time 285, 337
Reactivity 369
REM sleep 201
Reserpine 249
Response exitation 29
Response rate 395
Rotational behavior 54

S

Scopolamine 127
Secobarbital 93
Self-administration 19, 93, 115
Serotonin 237, 337
Sites of morphine action 219

Sleep 201, 285
—, changes 275
—, cycle 263
State-dependent learning 313
Stereotyped behavior 185
Stereotypy 361
Stress 44
Striatal dopamine 54
Sulpyrid 255

T

Taste aversion 79
Tetrabenazine 249
Tetrahydrocannabinols 62, 297, 337, 369, 401
THC effects 401
Thiordazine 185
Time estimation 285
Timing 62
Tolerance 146, 173, 369
Tremorine 249
Tryptamine 237
Tryptophan 140

U

Urine 1

V

Vanillylmandelic acid 1
Vigilance 285

W

Work test 10

Instructions to Authors

1. Papers will be published in **English, French or German.**

2. Authors should submit **manuscripts together with two copies.** The original illustration material (original drawings etc.) and two copies should be submitted together with the manuscript.

3. The text should be as **clear and concise** as possible. Both form and content of the paper should be carefully checked to exclude the need for corrections in proof. A charge will be made for changes introduced after the manuscript has been set in type.

4. **Manuscripts** should be typewritten, double-spaced, on one side of letter size paper and with wider margin on the left. The author should mark in the margin where figures and tables may be inserted. All pages should be numbered consecutively. Tables, footnotes and legends for illustrations should be typed (double-spaced) on separate pages. Use the metric system for text and figures.

5. The **first page** should bear:
the title; the name(s) of the author(s); the name of the laboratory where the work was carried out; a running title of not more than 67 typewriter strokes; footnotes to the title (marked by asterisks).

6. Each paper should be preceded by a brief **abstract** in English concerned with the methods used and with the experimental results which should be presented in such a way that it is possible for the reader to assess their significance. It should be as short as possible and should **not exceed 200 words.**
French and German articles should also have an **English translation of the title.**

7. Immediately following the abstract, some relevant **key words** should be supplied for subject indexing.

8. Articles dealing with **original investigations** should first state the problem concisely and arrange the material under Methods, Results, Discussion, References.

9. **Footnotes** should be kept to a minimum and numbered consecutively throughout the paper. Footnotes referring to the heading of the article are to be marked by asterisks.

10. The **bibliography** should include only work cited in the text. References should be listed alphabetically at the end of the paper as follows; *journal papers*—names and initials of all authors, full title, journal abbreviated in accordance with World Medical Periodicals, volume number, first and last page numbers, year in parentheses; *books*—names of authors, full title, edition, place, publisher, year. *Examples:*

Latz, A., Bain, G. T., Kornetsky, C.: Attenuated effect of chlorpromazine on conditioned avoidance as a function of rapid acquisition. Psychopharmacologia (Berl.) **14**, 23—32 (1969).

Fisher, S., Cole, J. O., Rickels, K., Uhlenhuth, E. H.: Drug set interaction: The effect of expectation on drug response in outpatients. In: Neuropsychopharmacology. Bradley, P. B., Flugle, F., and Hoch, P., eds., vol. 3, pp. 149—156. Amsterdam: Elsevier 1964.

Several publications by the same author or group of authors should be listed in chronological order; those that appear in the same year should be distinguished by the suffixes a, b, c etc. Citations in the text should be given in parentheses, e.g. (Beckman, 1958; Brown, 1963), except when the author's name is part of a sentence, e.g. "Man (1966) reported that . . ." When a paper with more than two authors is cited, all authors are named the first time, but subsequently only the first author, e.g. (Miller *et al.*, 1963).

11. Figures should be separated from the text and numbered. They should be restricted to a minimum. Descriptions in captions should not be expanded in the text, nor should the same data be given in both graph and table form. Coloured or previously published illustrations are not usually accepted. Original drawings and graphs should be drawn in Indian ink with lines of uniform thickness. Where possible, **figures should be grouped,** bearing in mind the maximum display area is 108 × 177 mm ($4^1/_4 \times 7''$). In general it should be assumed that the same degree of reduction will apply to all figures in the same paper. Inscriptions should allow for any reduction in scale—a capital letter should be about 1.8 mm high in the final version. If figures have to be redrawn for the blockmaker, this may cause considerable delay in publication. Photographs should be sharp, well-contrasted glossy prints at right angles. Authors should mark them with Letraset (Instant Lettering).

Handbuch der experimentellen Pharmakologie
Handbook of Experimental Pharmacology

Heffter-Heubner New Series Volume XXXI

R. Charlier: Antianginal Drugs

Pathophysiological, Haemodynamic, Methodological, Pharmacological, Biochemical and Clinical Basis for Their Use in Human Therapeutics

By **R. Charlier,**
Director of the Pharmacological Research Department,
LABAZ Research Center.
Lecturer,
Faculty of Medicine,
University of Liège,
Belgium

With 54 figures.
Approx. 440 pages.
Due October 1971.
Cloth DM 168,—

Springer-Verlag
Berlin
Heidelberg
New York

München London Paris
Tokyo Sydney

The book is a detailed and well documented survey of the antianginal drugs at present available. The introduction stresses the importance of the data acquired by catheterization of the heart in advancing our knowledge of angina pectoris. The heading "Coronary atherosclerosis" is mainly devoted to the general management of angina pectoris (general measures, physical training, surgery). In chapter I, the pathophysiology of angina pectoris is reviewed under three headings: the pathophysiology of the anginal attack, cardiac dynamics during the anginal attack, and the part played by hypersympathicotony in the anginal attack. This chapter ends with discussion of the criteria used in pharmacological research for the development of antianginal drugs. The second chapter is devoted to the physiological and haemodynamic basis underlying the pharmacology of the coronary circulation. In the third chapter, the pharmacological methodology for testing potential antianginal drugs is reviewed, comprising measurement of coronary flow, cardiac output, cardiac work and myocardial oxygen consumption. The fourth chapter deals with clinical methods for the assessment of the therapeutic value of antianginal drugs; methods of clinical evaluation are grouped according to their objective or subjective character, with a critical appreciation of their aims. The last chapter, which is the most widely documented, is devoted to the experimental and clinical pharmacology of antianginal drugs: nitrites (nitroglycerin and long-acting nitrates), several so-called coronary vasodilators, β-blocking agents, miscellaneous drugs and carotid sinus nerve stimulation. The book ends with a table of the main side effects in man, a list of more than 2500 references and a broad index of contents.

Responsible for advertisements: Edgar Seidler, D-1000 Berlin 15, Kurfürstendamm 237, Tel. (0311) 8830131, Telex: 01-82811
Springer-Verlag, Berlin, Heidelberg, New York
Printed in Germany by Wiesbadener Graphische Betriebe GmbH, D-6200 Wiesbaden
© by Springer-Verlag, Berlin Heidelberg 1972